• 3028 - A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA. (10%, 5 Votes)
• 911 - Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. (10%, 5 Votes)
• 1955 - Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months (10%, 5 Votes)
• 2987 - Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study (8%, 4 Votes)
• 1725 - Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis (6%, 3 Votes)
• 3225 - Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with RA (6%, 3 Votes)
• 86 - Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture (6%, 3 Votes)
• 1957 - No Increased Risk of Chronic Kidney Disease with Allopurinol Use (6%, 3 Votes)
• 3169 - Diagnostic Value of Ultrasound for the Diagnosis of Gout in a Prospective Cross-Sectional Study (6%, 3 Votes)
• 10L - Efficacy and Safety of Tofacitinib, an Oral JAK Inhibitor, in Patients with Active PsA and an Inadequate Response to TNF Inhibitors: OPAL Beyond, a RCT, Phase 3 Trial (4%, 2 Votes)
• 559 - Comparison of MD-HAQ-Based and PROMIS 29-Based RAPID3 for Assessing RA Disease Activity (4%, 2 Votes)
• 597 - Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015 (4%, 2 Votes)
• 604 - Sustained Efficacy/Comparable Safety/Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with RA (4%, 2 Votes)
• 2983 - Efficacy and Safety of Tofacitinib, an Oral JAK Inhibitor, or Adalimumab in Patients with Active PsA and an Inadequate Response to Conventional Synthetic Dmards: A RCT Phase 3 Trial. (4%, 2 Votes)
• 1586 - Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional DMARDs: A United States Subpopulation Analysis from Two Phase 3 Trials (2%, 1 Votes)
• 2001 - Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections (2%, 1 Votes)
• 969 - Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial (2%, 1 Votes)
• 1047 - Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability. (2%, 1 Votes)

Total Voters: 7